Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings
Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with:
- Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat metastatic disease.
- Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
As per global data analytics, global annual sales volumes of Eribulin Mesylate were at $392 million, including $153 million from the US, $126 million from Europe, and $112 million from the rest of the world. As of February 2022, Eribulin Mesylate (Halaven®) is approved in 39 countries worldwide.
To know more about our API offerings, please read the technical sheet on Eribulin Mesylate by filling the contact from below.
Explore other Whitepapers:Know More
Preencha o formulário de contato abaixo para visualizar o white paper